PRLD

Prelude Therapeutics Inc

• Reuters·03/19 23:40

  Prelude Therapeutics Chief Business Officer Sean P. Brusky files initial beneficial ownership statement

• TipRanks·03/18 18:55

  Prelude Therapeutics management to meet with Citizens

• Benzinga·03/17 20:33

  Prelude Therapeutics Announces Poster With Preclinical Data On Its Oral KAT6A Selective Degrader Accepted For Presentation At American Association For Cancer Research Annual Meeting 2026

• Reuters·03/17 20:31

  Prelude Therapeutics to present PRT13722 preclinical poster at AACR Annual Meeting 2026

• Reuters·03/17 20:31

  PRELUDE THERAPEUTICS ANNOUNCES ACCEPTANCE OF PRECLINICAL ABSTRACT FOR PRT13722, A FIRST-IN-CLASS ORAL KAT6A SELECTIVE DEGRADER AT THE 2026 AACR ANNUAL MEETING

• TipRanks·03/12 21:01

  Prelude Therapeutics Establishes New ATM Equity Offering Facility

• Reuters·03/12 20:32

  Prelude Therapeutics files prospectus supplement for up to USD 25 million at-the-market equity offering

• Dow Jones·03/11 11:47

  Prelude Therapeutics Is Maintained at Market Outperform by Citizens

• Benzinga·03/11 11:38

  Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

• TipRanks·03/11 09:15

  Prelude Therapeutics price target raised to $6 from $3 at Citizens

• Simply Wall St·03/10 23:28

  Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives

• TipRanks·03/10 12:47

  Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program

• Benzinga·03/10 11:40

  Prelude Therapeutics Earnings Report: Q4 Overview

• Seeking Alpha·03/10 11:30

  Prelude Therapeutics GAAP EPS of -$1.29 misses by $0.04, revenue of $12.14M

• Reuters·03/10 11:12

  Prelude Therapeutics FY2025 net loss fell 22% to USD 99.5 million